Loosening of clinical requirements has encouraged more projects into the IgA nephropathy pipeline, with a steroid–based approach from Sweden’s Calliditas looking…
Celgene’s surprise termination of a clinical trial makes for a day of soul-searching among other followers of the anti-CD47 approach.
Arbutus Biopharma already looked second best to Arrowhead Pharmaceuticals in the race to develop a functional cure for hepatitis B. New data have made the former’s task…
An October curse returns to haunt Convatec, and this time it has spooked the CEO.
The market clearance of the US’s first do-it-yourself hearing aid has knocked the traditional groups, but the real battle commences in 2020.
Abbott Laboratories has posted decent results for its transcatheter aortic valve, but all-important US pivotal data are in the offing.
After buying Avexis for $8.7bn to access a potentially transformative treatment for spinal muscular atrophy, data approaches from Novartis.
In the Rewind trial, whose readout is due by year-end, Trulicity needs to avert heart complications and show clean safety to keep up with other glucose-lowering drugs.
Forming partnerships with a number of players in diabetes technology is the key to growth, according to Ascensia Diabetes Care.
The UK company Midatech Pharma is giving up on speciality drugs to focus on cancer and rare diseases – and it has Novartis in its sights.
Voxeleron is, like Google’s related company Deepmind, using artificial intelligence to analyse ocular images. Unlike Deepmind, it is employing a targeted approach.